Content
71%Weight 40%Scale 1-5Reviews the quality of instructions and guidance provided to agents. Good implementation is clear, handles edge cases, and produces reliable results.
Highly actionable content with a clear five-phase workflow, concrete tool documentation, and executable examples throughout. The main weaknesses are repeated caveats that inflate token cost and a monolithic structure that inlines interpretation guidance which would be better split into a reference file.
Suggestions
Consolidate the direct-vs-indirect drug-target distinction into a single statement (Reasoning Strategy) and drop the repetitions in the network interpretation bullet and Evidence Grading table; likewise state the hsa-ID namespace caveat and the KEGG-coverage limitation once each.
Move the Evidence Grading table and Interpretation Guidance bullets into a references/ file (e.g., references/interpretation.md), keeping a two-line pointer in SKILL.md so the main file stays a lean overview.
Add a short fallback step at the end of the workflow (e.g., "If a phase returns no entries, verify the ID via KEGG_search_* before concluding KEGG lacks coverage") to make the existing implicit error handling an explicit validate-and-retry loop.
| Dimension | Reasoning | Score |
|---|---|---|
Conciseness | The body is mostly efficient (lean tool table, terse code blocks), but the same guidance is repeated: the direct-vs-indirect drug-target distinction appears three times (Reasoning Strategy, network interpretation, Evidence Grading), and both the hsa-ID namespace caveat and "KEGG coverage is not exhaustive" appear twice. This fits the mostly-efficient-but-could-be-tightened anchor at 3; it is not so padded as to match the 2 anchor's "several unnecessary explanations". | 3 / 5 |
Actionability | A 12-tool inventory with key params and returns, per-phase copy-paste-ready Python with real identifiers (H00031, D09996, hsa:672), expected result shapes ("result['data'] -> [{...}]"), and a complete worked end-to-end example fully cover the common cases, matching the 5 anchor. | 5 / 5 |
Workflow Clarity | The five phases are clearly sequenced with code for each, backed by a "LOOK UP DON'T GUESS" pre-check, an evidence-grading scheme, and error-path hints ("Failed conversions may indicate the gene is not in KEGG's curated set"). However there is no explicit validate-and-retry loop per phase, so it fits the most-checkpoints-present anchor at 4 rather than the explicit-feedback-loops anchor at 5; the destructive/batch cap at 3 does not apply since these are read-only lookups. | 4 / 5 |
Progressive Disclosure | A single ~190-line file with no bundle: the Evidence Grading table and multi-bullet Interpretation Guidance are reference-grade material that belongs in a separate file, and the skill is well beyond the under-50-line exception. Sections are well organized, but content that should be separate is inline, matching the 3 anchor rather than the 4 anchor's "most content appropriately placed". | 3 / 5 |
Total | 15 / 20 Passed |